Aura Biosciences (AURA) said Monday that data from a completed phase 1 trial of bel-sar in patients with non-muscle-invasive bladder cancer demonstrated a "robust anti-tumor immune response."
The company said the trial enrolled 15 patients, with primary endpoints of evaluating the safety and feasibility of bel-sar alone in five patients and bel-sar with light activation in 10 patients.
Clinical complete responses were observed with a single, low dose of bel-sar in patients with intermediate and high-risk non-muscle-invasive bladder cancer, supporting bel-sar's potential as a new treatment instead of, or ahead of, the standard of care procedure, the company said.
Bel-sar was also well tolerated as drug-related grade 1 events were reported in less than 10% of the patients, the company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。